来凯医药-B(02105)：LAE 002(Afuresertib)III期临床试验(AFFIRM-205)达到无进展生存期(PFS)的主要终点

智通财经04-15

智通财经APP讯，来凯医药-B(02105)发布公告，LAE 002(afuresertib)联合氟维司群，在既往接受内分泌联合或不联合CDK4/6抑制剂治疗后出现疾病进展，伴随PIK3CA/AKT1/PTEN改变的HR+/HER2-局部晚期或转移性乳腺癌(LA/mBC)患者中开展的III期临床试验“III期临床试验(AFFIRM-205)”)，取得强有力的积极顶线结果。此项关键性研究成功达到其...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2627473918?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-15 08:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627473918","market":"us","top_or_hot":-1,"title":"来凯医药-B(02105)：LAE 002(Afuresertib)III期临床试验(AFFIRM-205)达到无进展生存期(PFS)的主要终点","media":"智通财经","content":"<div>\n<p>智通财经APP讯，来凯医药-B(02105)发布公告，LAE 002(afuresertib)联合氟维司群，在既往接受内分泌联合或不联合CDK4/6抑制剂治疗后出现疾病进展，伴随PIK3CA/AKT1/PTEN改变的HR+/HER2-局部晚期或转移性乳腺癌(LA/mBC)患者中开展的III期临床试验“III期临床试验(AFFIRM-205)”)，取得强有力的积极顶线结果。此项关键性研究成功达到其...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1428595.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>来凯医药-B(02105)：LAE 002(Afuresertib)III期临床试验(AFFIRM-205)达到无进展生存期(PFS)的主要终点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n来凯医药-B(02105)：LAE 002(Afuresertib)III期临床试验(AFFIRM-205)达到无进展生存期(PFS)的主要终点\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-15 08:22 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1428595.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，来凯医药-B(02105)发布公告，LAE 002(afuresertib)联合氟维司群，在既往接受内分泌联合或不联合CDK4/6抑制剂治疗后出现疾病进展，伴随PIK3CA/AKT1/PTEN改变的HR+/HER2-局部晚期或转移性乳腺癌(LA/mBC)患者中开展的III期临床试验“III期临床试验(AFFIRM-205)”)，取得强有力的积极顶线结果。此项关键性研究成功达到其...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1428595.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4195","symbol_name":"互助储蓄与抵押信贷金融服务","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1428595.html","article_id":"2627473918","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627473918","pubTimestamp":1776212528,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"II期临床试验是一项多中心、随机、双盲、安慰剂对照的关键性研究，旨在评估该联合疗法的抗肿瘤疗效及安全性。.每日一次口服LAE 002的治疗，患者耐受性良好，因不良事件而中止治疗的比例极低。本集团有权就许可区域内LAE 002的未来净销售额收取梯度销售分成，分成比率在十余个百分点至二十余个百分点。本集团计划在中国以外地区寻求战略合作伙伴，以加速LAE 002在国际市场的开发及商业化。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4195":"互助储蓄与抵押信贷金融服务","BK4134":"信息科技咨询与其它服务","02105":"来凯医药-B","PFS":"Provident Financial Services Inc","III":"信息服务","BK4211":"区域性银行","BK1161":"生物科技"},"translate_title":"Laikai-B (02105): LAE 002 (Afuresertib) Phase III clinical trial (AFFIRM-205) reaches the primary endpoint of progression-free survival (PFS)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"III":1.5,"02105":1.5,"PFS":1.5},"content_text":"智通财经APP讯，来凯医药-B(02105)发布公告，LAE 002(afuresertib)联合氟维司群，在既往接受内分泌联合或不联合CDK4/6抑制剂治疗后出现疾病进展，伴随PIK3CA/AKT1/PTEN改变的HR+/HER2-局部晚期或转移性乳腺癌(LA/mBC)患者中开展的III期临床试验“III期临床试验(AFFIRM-205)”)，取得强有力的积极顶线结果。此项关键性研究成功达到其主要终点—在无进展生存期(PFS)方面，与对照组相比，展现出高度统计学显著且具有临床意义的改善。II期临床试验(AFFIRM-205)是一项多中心、随机、双盲、安慰剂对照的关键性研究，旨在评估该联合疗法的抗肿瘤疗效及安全性。共纳入261名受试者，其中70.5%的受试者曾接受过CDK4/6抑制剂治疗。.研究达到其主要终点，LAE 002(afuresertib)联合氟维司群组的中位PFS为7.6个月，安慰剂联合氟维司群组则为2.0个月，HR=0.33(p值<0.0001)。.每日一次口服LAE 002(afuresertib)的治疗，患者耐受性良好，因不良事件而中止治疗的比例极低。整体安全性特征与先前评估该联合疗法的数据一致。详细的研究结果将于即将召开的国际科学会议上公布。基于这项III期关键研究的积极结果，本集团将协同齐鲁制药有限公司(齐鲁制药)于近期向中国国家药品监督管理局(NMPA)药品审评中心(CDE)提交LAE 002(afuresertib)的新药上市申请(NDA)。本集团与齐鲁制药于2025年11月就中国地区签订了独家许可协议(许可协议)。根据许可协议，本集团有权获得最高总计人民币20.45亿元的首付款及里程碑款项。本集团有权就许可区域内LAE 002(afuresertib)的未来净销售额收取梯度销售分成，分成比率在十余个百分点至二十余个百分点。本集团计划在中国以外地区寻求战略合作伙伴，以加速LAE 002(afuresertib)在国际市场的开发及商业化。总体而言，约有50%的乳腺癌患者存在PIK3CA、AKT1或PTEN改变。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627473918","isCrawlerRequest":true}